Kornimate/medical-research-clean huggingface dataset:
molecular heterogeneity in multilobar low-grade gliomas

Conditions: Low-grade Diffuse Glioma

Summary: low-grade diffuse glioma (gdbg) are rare tumors of young adults, whose ontogenesis is poorly understood. patient management is based on the molecular profile defined by two molecular markers : mutations of the idh genes and chromosomal 1p19q co-deletion. to date, the idh and 1p19q statuses are determined on a single fragment collected from the tumor. in the case of gdbgs infiltrating several brain lobes, the sampling is done randomly on only one of the infiltrated lobes. an intra-tumoral heterogeneity of genetic alterations has been suggested and would impact management. phylogenetic analysis of genetic alterations found, by high throughput sequencing, in each lobe invaded by the same gdbg will make it possible to assess intra-tumoral heterogeneity and to discuss, at a fundamental level, the hypothesis of a single tumor site with secondary diffusion or that of the convergent progression of two or three distinct tumor sites. clinically, understanding the ontogenesis of gdbgs will improve their management because of the known link between brain location, dominant molecular profile, and prognosis.


Eligibility criteria:
inclusion criteria: * be over 18 years old. * subject not opposed to participating in the study * be scheduled in the operating room for the first surgery of a low-grade diffuse glioma presupposition on the basis of clinical and imaging criteria. * confirmation, after histopathological analysis of the resected tumor fragments, of the diagnosis of grade ii glioma according to the 2016 who classification of brain tumors. exclusion criteria: * patient minor, or major under legal protection, or unable to give consent. * refusal to participate in the study. * pathology diagnosis of grade iii glioma according to who 2016 classification * have received oncology treatment (chemotherapy and or chemotherapy) before the first surgery.

Keywords: low-grade diffuse glioma dna extraction sequencing
brief cbt for patients undergoing tavr

Conditions: Depression, Anxiety

Summary: adult patients scheduled to undergo tavr were randomized to receive brief bedside cognitive behavioral therapy for depression/anxiety or treatment as usual.

depression and anxiety are common symptoms in patients undergoing cardiac surgery and associated with increased cardiac morbidity and decreased functional status. cognitive behavioral therapy (cbt) has been shown to be an effective intervention to treat these symptoms after cardiac surgery, but has not yet been studied in patients undergoing less invasive cardiac procedures such as transcatheter aortic valve replacement (tavr). this study will examine the effect of cbt on symptoms of anxiety and depression in patients undergoing tavr. the cbt protocol was loosely structured on the managing depression and anxiety using education and skills (mades) protocol described in dao and colleagues (2011). the current intervention was designed to address the needs of individuals who may develop anxiety or depression symptoms post-tavr. the cbt intervention consisted of four 30 to 60-minute bedside treatment sessions with a trained clinician while the participant was hospitalized for tavr. main outcome measures were self-reported symptoms of depression and anxiety as measured by the beck depression inventory-ii and state trait anxiety inventory form y1. secondary outcomes included health related quality of life and hospital length of stay.

Eligibility criteria:
inclusion criteria: 1. adults 18 years of age and older 2. voluntary participation 3. informed consent obtained 4. patients with severe aortic stenosis and high surgical risk who are undergoing tavr exclusion criteria: 1. current psychiatric instability (eg., suicidality, schizophrenia, bipolar disorder, active alcoholism or substance abuse) 2. severe cognitive impairment, i.e. dementia 3. life threatening co-morbidities 4. inability to provide consent

Keywords: cbt brief therapy bedside intervention
sthlm3 as nordcap - a followup study of men on active surveillance of prostate cancer

Conditions: Prostate Cancer

Summary: the aim of the sthlm3 as nordcap study is to evaluate the stockholm3 test in an active surveillance cohort to predict upgrading on rebiopsy. the study follows a paired design, evaluating our proposed protocol for follow up men on active surveillance with stockholm3 versus the standard protocol according to national guidelines with psa.

sthlm3 as nordcap is a cross-sectional multi-center study, evaluating the predictive value of stockholm3 test in a prostate cancer cohort on as for upgrading on rebiopsy. men from the study sites, diagnosed with prostate cancer and currently on as and planned for rebiopsies will be invited to the study. eligible individuals have to be alive without any severe comorbidity and without a history of initiating treatment; surgery, radiation, hormone therapy or chemotherapy. to avoid the need for additional investigations, sampling will be synchronized with timing for planned follow-up within the as program for each individual. at baseline blood will be drawn for stockholm3 analyses. the patient will be asked to fill out an informed consent. for each man the following data will be collected: stockholm3 risk score, stockholm3 prostate volume cut-off, total psa, dre status, mri results (pi-rads, optional, only if mri is conducted within 3 months before biopsy), prostate volume, biopsy results (isup, cancer length, number of positive cores, total number of cores and stage). main outcome measurement will be number of upgrading, i.e. number of detected isup ≥ 2 cancers.

Eligibility criteria:
inclusion criteria: * men diagnosed with low-risk pc and currently on as and planned for follow-up with systematic and/or fusion biopsies as following standard of care. exclusion criteria: * history of treatment for prostate cancer; surgery, radiation, chemotherapy or hormonal treatment. * severe illnesses such as metastatic cancers, severe cardio-vascular disease or dementia

Keywords: active surveillance
evaluation of predictive factors for psoas tendinitis after first-line total hip arthroplasty

Conditions: Psoas Tendinitis

Summary: evaluation of predictive factors for psoas tendinitis after first-line total hip arthroplasty. a single-centre retrospective study of medical data from the medical records of patients undergoing total hip arthroplasty.

from the medical records of a series of patients operated on for total hip arthroplasty: main objective: to assess individual and surgical factors associated with the development of psoas tendinitis. secondary objectives: * to describe the frequency of occurrence of psoas tendinitis * to describe the outcome of patients who underwent tenotomy.

Eligibility criteria:
inclusion criteria: * patient aged 18 years or older, having been informed of the research * patient who has had a total hip replacement implanted for at least six months as a first-line treatment * patient who has been regularly monitored since the operation and for whom all clinical and radiological data are available during follow-up visits exclusion criteria: * patient undergoing revision surgery * patient who has indicated his opposition to the use of his medical data * patient under legal protection, guardianship or curators
exercise training to improve cognitive function

Conditions: Mild Cognitive Impairment

Summary: this project is assessing the feasibility of a novel home-based exercise intervention to improve episodic memory in individuals with mild cognitive impairment.

background/rationale: alzheimer's disease (ad) afflicts nearly 6 million americans, a number projected to grow in coming decades. ad is known to have a long preclinical phase in which pathophysiologic processes develop many years, even decades, before the onset of clinical symptoms. during this preclinical phase there is evidence of unremitting decline in cognitive function, particularly in episodic memory. thus far, evidence of the efficacy of pharmacological interventions to slow this decline in cognitive function has been limited, leading to increasing interest in the utility of nonpharmacological interventions including exercise. objective: the investigators propose to assess the feasibility of a novel home-based exercise intervention to improve episodic memory in veterans with mild cognitive impairment (mci). methods: the investigators will estimate the difference between the intervention (n=30) and the control group (n=30) on 6-month change in episodic memory (rey-osterrieth complex figure test, wechsler logical memory test) as well as the effect size, which will be used as a basis for sample size calculation for a proposed larger study. participants will be male and female veterans 50 years of age or older with amnestic mci.

Eligibility criteria:
inclusion criteria: * amnestic mci * ability to use a telephone without assistance exclusion criteria: * angina pectoris * history of myocardial infarction within 6 months * history of ventricular dysrhythmia requiring current therapy

Keywords: mild cognitive impairment exercise therapy patient adherence
pacap27 headache properties in migraine without aura patients

Conditions: Migraine Without Aura

Summary: pituitary adenylate cyclase-activating polypeptide (pacap) is a signaling molecule, localized in sensory and parasympathetic perivascular nerves fibres. pacap exists i to functional iso-forms pituitary adenylate cyclase-activating polypeptide-38 (pacap38) and pacap27.


Eligibility criteria:
inclusion criteria: * migraine patients meeting international headache society (ihs) criteria for migraine without aura of both sexes, 18-60 year, 50-100 kg. * fertile women should use safe contraception. fertile women do not include hysterectomized women or women who are postmenopausal for at least 2 years. safe contraception includes either intra uterine device (iud), birth control pills, surgical sterilization of the woman or depot progestogen. exclusion criteria: * tension type headache for more than 5 days the month on average in the last year. * all other primary headaches . * headache later than 48 hours before trial start. * daily intake of any medicine other than oral contraception. * ingestion of any form of medicinal product later than 4 times the plasma half-life substance (on trial day), except for oral contraception. * pregnant or breastfeeding women. * headache on the test day or later than 48 hours prior to administration of trial medicine / placebo * migraine within 5 days before the trial date. * ancestral information or clinical signs of (on the day of inclusion): * hypertension (systolic blood pressure\> 150 mmhg and / or diastolic blood pressure\> 100 mmhg) * hypotension (systolic blood pressure \<90 mm hg and / or diastolic blood pressure \<50 mmhg) * cardiovascular disease of all kinds, including cerebrovascular disease. * anamnestic or clinical signs of mental illness or abuse. * patients with glaucoma or prostatic hyperplasia * anamnestic or clinical signs of diseases of any kind such as the investigating physician is considered relevant for participation in the trial.
treatment with radiolabeled monoclonal antibody huj591-gs (177lu-j591) in patients with metastatic prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to find out how effective 177lu -j591 is in the treatment of patients with metastatic, androgen-independent prostate cancer.

to determine the clinical activity of 177lu -j591 for the treatment of patients with metastatic, androgen-independent prostate cancer. patients will receive a single dose of j591 (total antibody of 20 mg) consisting of antibody chelated with 177lu at a dose of 65 or 70 mci/m2 with a specific activity of 12-15 mci/mg plus non-radiolabeled antibody.

Eligibility criteria:
inclusion criteria: * histologic diagnosis of prostate adenocarcinoma. * metastatic prostate cancer progressive on imaging studies and/or rising psa despite adequate medical or surgical castration therapy. * progressed following discontinuation of anti-androgen therapy, if received. * serum testosterone \< 50 ng/ml exclusion criteria: * use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of treatment. * use of pc-spes within 4 weeks of treatment. * use of red blood cell or platelet transfusions within 4 weeks of treatment. * use of hematopoietic growth factors within 4 weeks of treatment. * prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment. * bone scan demonstrating confluent lesions involving both axial and appendicular skeleton. * prior radiation therapy encompassing \>25% of skeleton. * prior treatment with 89strontium or 153samarium containing compounds (e.g. metastron®, quadramet®). * active angina pectoris or ny heart association class iii-iv. * history of deep vein thrombophlebitis and/or pulmonary embolus within 3 months of study entry. * other serious illness(es) involving the cardiac, respiratory, cns, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study. * prior monoclonal antibody therapy with the exception of prostascint® * prior investigational therapy (medications or devices) within 6 weeks of treatment. * known history of hiv

Keywords: prostate cancer
prevalence of keratoconus in inflammatory bowel diseases

Conditions: Inflammatory Bowel Diseases; Keratoconus

Summary: a retrospective study has shown the association between the inflammatory bowel diseases (ibd) and the presence of a keratoconus. this new study will measure the prevalence of keratoconus and follow its activity in patients affected by ibd and followed up in hepatology-gastroenterology department at nancy hospital. the prevalence of keratoconus will be compared to known data of literature about general population. the secondary purpose is to search for a relationship between the presence of a keratoconus and activity criteria of ibd. perspectives are a systematic screening for keratoconus in patients affected by ibd with the amelioration of the ophthalmologic care of ibd patients and confirmation of the recent hypothesis of inflammatory origin of keratoconus.


Eligibility criteria:
inclusion criteria: * informed consent * affiliation to social security plan * diagnosis of ibd since more than 3 years, under treatment or not exclusion criteria: * protected person * pregnant or breastfeeding women * person in life-and-death emergency * person deprived of liberty * refusal to remove contact lenses, where necessary
inova cardiogenic shock registry (inova shock)

Conditions: Cardiogenic Shock

Summary: to collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus historical survival rates. to collect inova heart and vascular institute (ihvi) site specific outcomes before and after initiation of the cardiogenic shock team on january 1, 2017. to collect outcomes related to implementation of mechanical circulatory support versus no circulatory intervention and type of intervention (extracorporeal membrane oxygenation (ecmo) versus intracorporeal axial-flow (impella). • assess survival at three time points.

any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the inova heart and vascular institute shall be included in this registry. this includes adults with and without decision making capacity over the age of 18 years old. the primary investigator (pi) will designate the data points to be included in the database in order to assess the efficiency of procedures and protocols in the treatment of cardiogenic shock at the ihvi as administered by the shock team, to identify relationships between treatment and negative morbidity and mortality outcomes, and to monitor and improve quality of care delivered.

Eligibility criteria:
inclusion criteria: -patients at the ihvi with documented cardiogenic shock team intervention for acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock. exclusion criteria: -patients under the age of 18 will be excluded.

Keywords: cardiogenic shock
a study to assess the effectiveness and safety of ozanimod in chinese adults with relapsing multiple sclerosis

Conditions: Relapsing Multiple Sclerosis

Summary: the purpose of this study is to assess the effectiveness and safety of ozanimod in chinese adults with relapsing multiple sclerosis.


Eligibility criteria:
inclusion criteria * participants must have multiple sclerosis (ms) as diagnosed by the 2017 revision of the mcdonald criteria. * participants must be exhibiting a relapsing clinical course consistent with relapsing multiple sclerosis (rms) and history of brain mri lesions consistent with ms. * participants must have an edss score between 0 and 5.0 (both inclusive) at baseline. exclusion criteria * participants must not have primary progressive ms at screening. * participants must not be diagnosed with, or suspected to have neuromyelitis optica spectrum disorder (nmosd) by clinical symptoms, mri appearance, and/or supportive serologies according to international consensus criteria.28 a positive test for aquaporin-4 (aqp4) by history or at screening is exclusionary. * participants must not have clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, renal, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study in the opinion of the investigator. * specific cardiac conditions are excluded, including history or presence of:. i) recent (within the past 6 months) occurrence of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, new york heart association (nyha) class iii/iv heart failure, or severe untreated sleep apnea. ii) second-degree (mobitz type ii) atrioventricular (av) block, third-degree av block, sick sinus syndrome, or sino-atrial block unless participants have a pacemaker in place. iii) prolonged corrected qt interval by fredericia's formula (qtcf; \> 450 msec males and \> 470 msec females), or participants at additional risk for qt prolongation. * participants must not have diabetes mellitus type 1 or uncontrolled diabetes mellitus type 2 with hemoglobin a1c \> 9%, or diabetic participants with significant comorbid conditions such as retinopathy or nephropathy. * participants must not receive a live vaccine or a live-attenuated vaccine within 4 weeks prior to first dose or planning to receive a live vaccine or a live-attenuated vaccine during the study or within 28 days after discontinuation from study intervention. * participants must not have a history of any significant drug allergy (such as anaphylaxis or hepatotoxicity). * other protocol-defined inclusion/exclusion criteria apply.
effects of fetal, infant, and early childhood exposures on adult cancer risk in women

Conditions: Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: gathering information about pregnancy, infancy, and early childhood exposures may help doctors identify cancer risk factors, and may help the study of cancer. purpose: this natural history study is looking at the effects of fetal, infant, and early childhood exposures on adult cancer risk in women.

objectives: * determine if fetal, infant, and early childhood exposures are associated with adult cancer risk in women. outline: mothers of nurses complete questionnaires to collect maternal data, such as pregnancy weight gain, diet during pregnancy, maternal pre-eclampsia, gestational diabetes, gestational age at birth, birth weight, and infant feeding practices. maternal data is linked to other data collected from critical time periods in the nurses's life cycle, such as menarche, first pregnancy, or adult dietary intake.

Eligibility criteria:
disease characteristics: * mother of a nurse who is a participant in the nurses' health studies i and ii * nurse free of cancer in the year 2000 patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: breast cancer unspecified adult solid tumor, protocol specific
classic vs. high-fat intermittent fasting effects

Conditions: Obesity

Summary: poor eating habits contribute to weight gain and obesity, leading to numerous metabolic issues such as diabetes and cardiovascular diseases. the treatment of obesity involves lifestyle interventions that include dietary and nutritional modifications, physical activity, and behavioral therapy. literature supports both carbohydrate and fat restriction in the treatment of obesity. in low-carbohydrate diets, less than 40% of energy is sourced from carbohydrates.besides the dietary model, individual eating behavior can also influence the diet's outcomes. there is a significant relationship between eating behavior and food choices. given that food choices can impact diet satisfaction, evaluating eating behavior is important when assessing dietary compliance.the literature includes studies demonstrating the effects of a classic intermittent fasting diet. however, no studies have compared the potential effects of intermittent fasting models based on the macronutrient distribution within their content. therefore, this study aims to evaluate the effects of high-fat, low-carbohydrate intermittent fasting versus classical intermittent fasting on body composition, eating behavior, and diet satisfaction.


Eligibility criteria:
inclusion criteria: * 18-65 years old * no chronic disease * female * volunteering exclusion criteria: * hypoglycemia * eating disorders * pregnant and lactating women

Keywords: intermittent fasting diet body composition eating behavior diet satisfaction
long term prospective study evaluating effectiveness of narrow margins for low-risk head and neck basal cell carcinomas

Conditions: Basal Cell Carcinoma

Summary: the purpose of this study is to determine the narrowest excision margin for head and neck basal cell carcinoma (bcc) tumors satisfying the national comprehensive cancer network® (nccn) low-risk for recurrence clinical and histopathological criteria that gives an acceptable (95%) clinical cure-rate over a 3 year follow-up period. margins of 1 and 2mm are evaluated.

basal cell carcinoma (bcc) is the most common skin cancer in the us. most are treated by surgical excision. excision margins vary by tumor size, anatomic location, histological subtype, and surgeon preference. published recommendations and follow up observation times vary. current clinical practice supports the 4 mm excision margin; however, this can be a disservice to the patient by potentially excising additional normal tissue unnecessarily and yielding larger scars. considering healthcare costs, both the excision and repair components are usually billed by size measurements. determining the narrowest excision margin to give an acceptable clinical cure could feasibly reduce this expenditure.

Eligibility criteria:
inclusion criteria: * patient has a bcc \<10mm on their cheeks, forehead, scalp \& neck or \<6mm on their central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular \& postauricular, temple \& ear * the bcc has well defined borders * the bcc is primary * the patient is not immunosuppressed * the bcc is not located at a site of prior radiation therapy * the histologic subtype is nodular or superficial * there is no perineural involvement exclusion criteria: * patient has a bcc \>or=10mm on their cheeks, forehead, scalp \& neck or \>or=6mm on their central face, eyelids, eyebrows, periorbital, nose, lips, chin, mandible, preauricular \& postauricular, temple \& ear * the bcc has poorly defined borders * the bcc is recurrent * the patient is immunosuppressed * the bcc is located at a site of prior radiation therapy * the histologic subtype is aggressive * there is perineural involvement